<DOC>
	<DOCNO>NCT00794547</DOCNO>
	<brief_summary>According Cancer Atlas , lung cancer remain major cancer among 10.9 million new case cancer diagnose annually worldwide . The mortality lung cancer great combine mortality breast , colon prostate cancer combine . Most patient metastatic non-small-cell lung cancer ( NSCLC ) treat platinum-based chemotherapy regimen . The drug combination cisplatin docetaxel one commonly use regimens metastatic NSCLC . Although drug powerful disruptors cell growth , positive therapeutic response rate therapy remain low NSCLC patient , 25 % 30 % . While add new biologics bevacizumab current treatment standard improve treatment response , median survival advance NSCLC patient receive type treatment remain low 12 month . Research study demonstrate Vitamin D , 's signal pathway important biological target cancer therapeutic . In vitro vivo calcitriol ( 1 , 25 dihydroxycholecalciferol ) antiproliferative potentiates antitumor effect cytotoxic agent ( e.g . taxanes , platinum analogue ) . We show administration high dos calcitriol cisplatin feasible associate complete tumor regression dog spontaneous cancer . Calcitriol also show synergistic docetaxel preclinical well recent phase II clinical trial prostate cancer . Based result support data study indicate calcitriol function potent well tolerate anti-tumor agent use combination drug like cisplatin docetaxel , hypothesize introduce calcitriol treatment regime NSCLC patient potential demonstrably improve treatment response patient . The overall goal conduct phase I/II clinical study ( 1 ) determine maximum tolerate dose ( MTD ) dose limit toxicity ( DLT ) calcitriol combination cisplatin/docetaxel patient advance NSCLC , ( 2 ) ass response rate patient advance NSCLC combination calcitriol cisplatin/docetaxel , ( 3 ) evaluate pharmacokinetics ( PK ) administer calcitriol intravenously MTD , ( 4 ) evaluate correlation calcitriol PK change specific cod region gene associate calcitriol breakdown .</brief_summary>
	<brief_title>Phase I/II Calcitriol Lung Cancer</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Calcitriol</mesh_term>
	<criteria>1 . Proven histological cytological diagnosis stage IIIB ( malignant pleural effusion ) IV NSCLC . 2 . Age 18 year 3 . Performance status must ECOG 01 . 4 . No prior concurrent malignancy , except nonmelanoma skin cancer , CIS cervix , unless document diseasefree 2 year . 5 . No prior use chemotherapy stage IV NSCLC ; Adjuvant therapy permit . 6 . Adequate bone marrow , hepatic , renal function , evidence following : WBC 3.0 x 109/L , neutrophils 1.5 x 109 /L ; platelet count 100 x 109/L ; Hgb &gt; 10 g/dL ( may transfuse 10g/dL ) ; total bilirubin within upper limit institutional normal range ; ( transaminase SGOT SGPT ) 1.5 time upper limit institutional normal range . Creatinine within upper limit institutional normal range ; creatinine clearance &gt; 50 ml/min 7 . Patients must measurable evaluable disease ( required phase I part study ) 8 . Normal cardiac function history uncontrolled heart disease 9 . Female patient must pregnant ; must postmenopausal practice accepted form birth control . If pregnancy possibility , pregnancy test require prior initiation therapy . 10 . Life expectancy least 12 week . 11 . Patient investigator sign studyspecific consent form , indicate investigational nature study 12 . Patients must accessible treatment followup . 13 . No chemotherapy radiotherapy within 3 week study entry define day 1 therapy calcitriol plus chemotherapy ( 6 week mitomycin C nitrosourea ) . 14 . No treatment investigational drug within 3 week study entry . 15 . No serious illness medical condition include unstable cardiac disease require treatment , new onset crescendo rest angina ; history significant neurological psychiatric disorder include psychotic disorder , dementia , seizures ; active infection permit . No evidence grade &gt; 2 peripheral neuropathy . No history severe hypersensitivity reaction docetaxel drug formulate polysorbate 80 16 . Palliative radiation permit ( long marrow expose great 10 % ; please see Appendix IV reference ) At least 1 week since last palliative XRT . 17 . Treated brain metastasis allow wait period follow gamma knife least 2 week whole brain XRT long neurologically stable . 1 . Known hypersensitivity Vitamin D , docetaxel , cisplatin 2 . Hypercalcemia ( patient serum albumin correct calcium* &gt; 10.7 mg/dL ) 3 . History renal/bladder stone past 10 year 4 . History nephrectomy . 5 . Uncontrolled heart disease , unstable angina , heart failure , current digoxin therapy 6 . Thiazide , Digoxin glucocorticoid therapy ( except premedication Dexamethasone use study prescribe ) 7 . Unwillingness stop calcium supplementation 8 . Concurrent use Phenytoin , Barbiturates , Rifampin , Carbamazepine , Phenobarbital St John 's wort . 9 . Treatment investigational drug within 3 week Day 1 protocol 10 . Any unresolved toxicity ( NCI CTCAE version 3.0 , &gt; 2 ) ( Please see appendix V link ) 11 . Pregnancy/Lactation 12 . Patients IIIB NSCLC eligible definitive chemoradiation . Ca correct = Ca ( measure ) + ( 0.8 x ( 4 albumin ) )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2015</verification_date>
	<keyword>lung cancer ; nsclc</keyword>
</DOC>